OBJECTIVE: Determine whether enhanced labor ward-based services for prevention of mother-to-child transmission of HIV (PMTCT) would improve nevirapine (NVP) coverage. DESIGN: Cluster-randomized trial at 12 public-sector delivery centers in Lusaka, Zambia. METHODS: Following a baseline surveillance period, 12 labor wards were randomized, six to offer opt-in HIV testing to women of unknown serostatus (with NVP administration as indicated) and to assess NVP adherence among known HIV-infected women. The six control labor wards provided the standard of care. The NVP coverage endpoint was defined as the proportion of HIV-infected/exposed women/infant pairs with confirmed NVP ingestion. We used generalized estimating equations (GEE) to determine the odds of coverage associated with the intervention and ultimately used the parameters for the estimated GEE model to estimate relative risk. RESULTS:Between October 2005 and January 2006, 7664 women gave birth at participating clinics. We collected anonymous-linked blood from 7592 (99%) umbilical cords; tested 7438 (97%) for HIV, 1618 (22%) were seropositive, and of these, 1279 (79%) were tested for NVP. At baseline (preintervention), the probability of HIV-infected/exposed women/infant pairs receiving NVP in treatment clinics (42%) was 0.89 times the probability of being covered in control clinics (53%) whereas during the intervention period the probability of treatment clinic coverage (52%) was 1.22 the probability control clinic coverage (43%), representing a multiplicative effect of 1.37 upon the RR at baseline (ratio of relative risks 1.37, bootstrapped 95% CI, 1.04-1.77). CONCLUSION: Labor ward-based PMTCT programs are feasible and can have a significant, positive impact on NVP coverage.
RCT Entities:
OBJECTIVE: Determine whether enhanced labor ward-based services for prevention of mother-to-child transmission of HIV (PMTCT) would improve nevirapine (NVP) coverage. DESIGN: Cluster-randomized trial at 12 public-sector delivery centers in Lusaka, Zambia. METHODS: Following a baseline surveillance period, 12 labor wards were randomized, six to offer opt-in HIV testing to women of unknown serostatus (with NVP administration as indicated) and to assess NVP adherence among known HIV-infectedwomen. The six control labor wards provided the standard of care. The NVP coverage endpoint was defined as the proportion of HIV-infected/exposed women/infant pairs with confirmed NVP ingestion. We used generalized estimating equations (GEE) to determine the odds of coverage associated with the intervention and ultimately used the parameters for the estimated GEE model to estimate relative risk. RESULTS: Between October 2005 and January 2006, 7664 women gave birth at participating clinics. We collected anonymous-linked blood from 7592 (99%) umbilical cords; tested 7438 (97%) for HIV, 1618 (22%) were seropositive, and of these, 1279 (79%) were tested for NVP. At baseline (preintervention), the probability of HIV-infected/exposed women/infant pairs receiving NVP in treatment clinics (42%) was 0.89 times the probability of being covered in control clinics (53%) whereas during the intervention period the probability of treatment clinic coverage (52%) was 1.22 the probability control clinic coverage (43%), representing a multiplicative effect of 1.37 upon the RR at baseline (ratio of relative risks 1.37, bootstrapped 95% CI, 1.04-1.77). CONCLUSION: Labor ward-based PMTCT programs are feasible and can have a significant, positive impact on NVP coverage.
Authors: Monique van Lettow; Richard Bedell; Megan Landes; Lucy Gawa; Stephanie Gatto; Isabell Mayuni; Adrienne K Chan; Lyson Tenthani; Erik Schouten Journal: BMC Public Health Date: 2011-06-03 Impact factor: 3.295
Authors: Marco T Luque; Cathy A Jenkins; Bryan E Shepherd; Denis Padgett; Vanessa Rouzier; Regina Célia M Succi; Daisy M Machado; Catherine C McGowan; Sten H Vermund; Jorge A Pinto Journal: J Pediatr Date: 2017-01-09 Impact factor: 4.406
Authors: Carolyn M Audet; Meridith Blevins; Yazalde Manuel Chire; Muktar H Aliyu; Lara M E Vaz; Elisio Antonio; Fernanda Alvim; Ruth Bechtel; C William Wester; Sten H Vermund Journal: AIDS Behav Date: 2016-09
Authors: Melanie A Thompson; Michael J Mugavero; K Rivet Amico; Victoria A Cargill; Larry W Chang; Robert Gross; Catherine Orrell; Frederick L Altice; David R Bangsberg; John G Bartlett; Curt G Beckwith; Nadia Dowshen; Christopher M Gordon; Tim Horn; Princy Kumar; James D Scott; Michael J Stirratt; Robert H Remien; Jane M Simoni; Jean B Nachega Journal: Ann Intern Med Date: 2012-03-05 Impact factor: 25.391
Authors: Holly E Rawizza; Charlotte A Chang; Beth Chaplin; Isah A Ahmed; Seema T Meloni; Tinuade Oyebode; Bolanle Banigbe; Atiene S Sagay; Isaac F Adewole; Prosper Okonkwo; Phyllis J Kanki Journal: Curr HIV Res Date: 2015 Impact factor: 1.581
Authors: Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Tajanna Stinn; Steve Kuntz; Dana Varon; Meei-Li Huang; Stacy Selke; Samuel Njikan; Emily S Ford; Joan Dragavon; Robert W Coombs; Christine Johnston; Marta E Bull Journal: J Virol Date: 2020-12-09 Impact factor: 5.103
Authors: Jean B Nachega; Olalekan A Uthman; Jean Anderson; Karl Peltzer; Sarah Wampold; Mark F Cotton; Edward J Mills; Yuh-Shan Ho; Jeffrey S A Stringer; James A McIntyre; Lynne M Mofenson Journal: AIDS Date: 2012-10-23 Impact factor: 4.177